MICA · CARE LEARNING NOTES
Observe, keep care safe and communicate
Rituximab requires coordinated preparation: specialist prescribing, formulation identification, infection checks and close observation. This adult guide explains safety checks; technical parameters require validation for the product actually available.
Identify the presentation
The documentary reference is MabThera 100 mg concentrate for solution for infusion, Roche, UK SmPC. The number on the vial identifies its presentation, not the individual prescription. Compare brand, substance, form, prescribed route, expiry and batch. The subcutaneous formulation is distinct: a similar name does not permit substitution. The UK SmPC confirms neither Algerian availability nor authorisation.
[1]Check the record before administration
Check for current infection, previous reactions, expected laboratory results and medical review of hepatitis B screening. A negative HBsAg is insufficient when anti-HBc antibodies are positive: communicate this to the prescriber and verify the specialist plan. Confirm prescribed premedication and prophylaxis rather than copying a previous session.
[1][2]Recognise a reaction during the session
Record baseline observations and ensure immediate access to the emergency team and equipment. Chills, fever, rash, chest tightness, dyspnoea or hypotension require immediate reporting. Respiratory or circulatory compromise requires immediate interruption of the suspected infusion and activation of the emergency protocol. The mechanism may be allergic or cytokine-related; diagnosis must not delay escalation.
[1]Before treatment, check that hepatitis B screening and prescribed measures have been arranged. During and after infusion, do not dismiss chest tightness, breathlessness or blood pressure changes. Restarting and its rate require a medical decision consistent with official product information, never an automatic restart.
- Hand over product name, rate at reaction onset and actions already taken.
Arrange continuity of care
Document product, batch, times, symptoms and medical decisions. Restart requires a documented decision. Explain that fever or infection after the session, and new or progressive neurological symptoms, warrant prompt assessment. Provide instructions and the alert card appropriate to the indication, with a clearly identified contact.
[1][2]A learning situation
FICTIONAL SITUATION · REFLECTION WITHOUT A SCORE
Fictional situation: before the first session, the nurse finds positive anti-HBc and negative HBsAg; no plan is documented.
Can screening be considered reassuring?
References and scope
- MabThera 100 mg Concentrate for Solution for Infusion — SmPC (UK) ↗
- Rituximab: screen for hepatitis B virus before treatment ↗
Original documentary teaching summary for adult care. Procedures and medicines depend on professional competence, prescription and institutional procedures. International references do not establish an Algerian protocol. Independent human scientific review remains to be confirmed.